Abeykoon Jithma P, Tawfiq Reema K, Kumar Shaji, Ansell Stephen M
Division of Hematology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Fac Rev. 2022 Nov 29;11:34. doi: 10.12703/r/11-34. eCollection 2022.
Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant state for a spectrum of lymphoplasmacytic malignancies. The risk of progression of MGUS to a symptomatic therapy requiring plasma cell dyscrasia is about 1% per year. Studies carried out over the previous 10 years have improved risk stratification of MGUS based on serologic and genomic evaluations, which has led to better management of patients. In this review, we address the epidemiology, diagnosis, and pathogenesis of MGUS and discuss risk-adapted best practice approaches to monitor patients.
意义未明的单克隆丙种球蛋白病（MGUS）是一系列淋巴浆细胞恶性肿瘤的癌前状态。MGUS进展为需要浆细胞发育异常的症状性疾病的风险约为每年1%。过去10年进行的研究基于血清学和基因组评估改进了MGUS的风险分层，从而实现了对患者的更好管理。在本综述中，我们阐述了MGUS的流行病学、诊断和发病机制，并讨论了针对风险的最佳监测患者实践方法。
